NCT07013591

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Detailed description

This is a phase 2a, randomized, double-blind, parallel-group, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery. A total of 90 patients will be randomized 1:1:1 to placebo or to one of two dosing regimens of NMN seven days prior to surgery as follows: Arm A: NMN 1,000 mg PO twice daily, administered for 7 days preoperatively, on the day of surgery, and for 4 days postoperatively Arm B: NMN 1,000 mg PO twice daily, administered for 2 days preoperatively, on the day of surgery, and for 4 days postoperatively Arm C: Placebo PO twice daily, administered for 7 days preoperatively, on the day of surgery, and for 4 days postoperatively There are two major study aims: Aim 1: Test the effect of oral NMN administration on myocardial NAD+ concentration. Aim 2: Test the effect of oral NMN administration on postoperative myocardial and kidney injury parameters.

Conditions

• Coronary Artery Bypass Graft

Interventions

Type	Name	Description
DRUG	MIB-626	An orally-administered stable crystalline tablet formulation of NMN
OTHER	Placebo	matching placebo tablets

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-10-01
• Completion: 2029-01-01
• First posted: 2025-06-10
• Last updated: 2026-02-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study